GLP-1 & weight-loss clinical trials in Georgia
10 GLP-1 or weight-loss trials are recruiting in Georgia as of July 14, 2026, with sites in Albany, Atlanta, Columbus, Conyers, Decatur and more. Many studies reimburse time and travel — the amount is set by each study and confirmed when you contact the team.
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Phase 4 · ~200 participants · NCT06864026
Studied intervention: Tirzepatide
Georgia sites: Marietta, Waycross
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Phase 3 · ~800 participants · NCT07153471
Studied intervention: Orforglipron
Georgia sites: Decatur, Woodstock
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Phase 3 · ~125 participants · NCT06672549
Studied intervention: Orforglipron
Georgia site: Atlanta
- Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Phase 3 · ~1200 participants · NCT07284979
Studied intervention: Semaglutide
Georgia site: Albany
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Phase 3 · ~2500 participants · NCT07564414
Studied intervention: Semaglutide
Georgia sites: Conyers, Gainesville, Roswell, Woodstock
- A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Phase 3 · ~1000 participants · NCT07202884
Studied intervention: Orforglipron
Georgia site: Lawrenceville
- A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Phase 4 · ~200 participants · NCT06857942
Studied intervention: Tirzepatide
Georgia site: Douglasville
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Phase 3 · ~150 participants · NCT06672939
Studied intervention: Orforglipron
Georgia site: Atlanta
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Phase 3 · ~460 participants · NCT07253285
Studied intervention: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Georgia sites: Atlanta, Columbus, Decatur, Snellville
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Phase 2 · ~200 participants · NCT07446998
Studied intervention: Semaglutide (Wegovy) weekly injection
Georgia site: Atlanta
What joining a GLP-1 trial in Georgia actually involves
Every study above is registered on ClinicalTrials.gov, the US National Library of Medicine's public registry, and each link goes straight to that record — the one place the eligibility criteria, the schedule of visits and the contact details are kept current. A recruiting listing means the study is actively enrolling; it does not mean you are eligible until the study team screens you.
- Reimbursement is not the same as payment. Many studies cover time and travel, but the amount is set per study and confirmed by the team — treat any specific figure you see elsewhere as unverified until they tell you.
- You may receive a placebo. Most of these are randomized, so joining is not a guaranteed route to the active drug. That is worth weighing if your goal is treatment rather than contributing to the evidence.
- Trial participation is free to join and separate from a prescription. If your aim is to start a GLP-1 now, compare the cash-pay routes instead — trials are a different path with a different purpose.
Source: ClinicalTrials.gov (US National Library of Medicine), public-domain data, snapshot July 14, 2026. This is not medical advice or a recruitment service — confirm status, eligibility, and compensation on each linked ClinicalTrials.gov record and discuss any trial with your clinician.